参考文献/References:
[1] 周自强,胡大一,陈捷,等.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494.
[2] 杨萌萌,范新荣,蔡琳.盐酸关附甲素抗心律失常研究进展[J].心血管病学进展,2013,34(5):660-664.
[3] 王智勇,郭继鸿,许原.盐酸关附甲素终止阵发性室上性心动过速的临床研究[J].中国实用内科杂志,2002,22(4):212-213.
[4] 韩智红,吴学思,贾世杰,等.盐酸关附甲素注射液对室性早搏的疗效与安全性观察[J].心肺血管杂志,2003,22(3):144-146.
[5] Yang YM,Zhu J,Gao X,et al.Effect of Guanfu base A patients with ventricular arrhythmias[J].Chin J Cardiol,2006,34(4):329-332.
[6] Mccarty MF. Practrcal prevention of cardiac remodeling and atrial fibrillation with full-spectrum antioxidant therapy and ancillary strategies[J].Med Hypotheses,2010,75(2):141-147.
[7] Arora S,Vaishya R,Dabla PK,et al.NAD(P)H oxidases in coronary artery disease[J].Adc Clin Chem,2010,50:65-86.
[8] 陈清,魏丕敬,顾培坤,等.关附甲素对培养心肌细胞“缺氧缺糖”的保护作用[J].药学实践杂志,2000,18(5):331-333.
[9] 郭巧,孙建国,黄潞,等.关附甲素抗氧化和抗心房颤动作用[J].中国药科大学学报.2015,46(2):235-241.
[10] 王曼,朱俊,杨艳敏,等.盐酸关附甲素对豚鼠离体心房肌电生理特性作用的研究[J].中国分子心脏病学杂志,2012,12(3):182-185.
[11] Tang YQ,Yin YM,Huang L,et al.Effects of Guanfu total base on experimental atrial fibrillation[J].Guide Chin Med,2011,9(36):249-251.
[12] 王曼,朱俊,杨艳敏,等.盐酸关附甲素在犬迷走神经性心房颤动模型中的作用[J].中国心脏起搏与心电生理杂志,2008,2(2):148-152.
[13] Kato T, Iwasaki YK, Nattel S. Connexins and atrial fibrillation:filling in the gaps[J]. Circulation,2012,125:203-206.
[14] Dhein S, Rothe S, Busch A, et al. Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation[J]. Br J Pharmacol,2011,164:607-616.
[15] Wirka RC, Gore S,van Wagoner DR, et al. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation[J]. Circ Arrhythm Electrophysiol,2011,4:87-93.
[16] Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation[J]. Circulation,2012,125: 216-225.
[17] 丽英,杨艳敏,浦介麟,等.盐酸关附甲素对豚鼠心室肌细胞膜钠通道的阻断作用[J].中华心律失常杂志,2007,11(1):47-52;
[18] Burashnikov A,Dldiego JM,Zygmunt AC,et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation:differences in sodium channel inactivation between atria and ventricles and the role of ranolazine[J].Circulation,2007,116(13):1449-1457.
[19] Undrovinas NA, Maltsev VA, Belardinelli L,et al. Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure[J]. J Physiol Sci,2010,60(4): 245-257.
[20] Charles A,Vladislav N,John CS,et al.The role of late sodium current in development of cardiac arrhythmias[J].Handb Exp Pharmacol,2014,221:137-168.
[21] Persson F, Andersson B, Duker G,et al. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre[J]. Eur J Pharmacol,2007,558(1-3):133-143.
[22] Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes[J]. Pharmacol Ther,2012,133(3):311-323.
[23] Fredj S, Lindegger N, Sampson KJ,et al. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes[J]. Circ Res,2006,99(11):1225-1232.
[24] Burashnikov A,di Diego JM,Zygmtmt AC,et al.Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation:differences in sodium channel inactivation between atria and ventricles and the role of ranolazine[J].Circulation,2007,116:1449.
[25] 贺鹏康,霍勇,周菁,等.晚钠电流抑制剂对心房间传导的影响及其抗心房颤动作用的机制探讨[J].中华心律失常学杂志,2014,18(1):52-56.
[26] Jin SS, Guo Q, Xu J, et al. Antiarrhythmic ionic mechanism of Guanfu base A selective inhibition of late sodium current in isolated ventricular myocytes from guinea pigs[J]. Chin J Nat Med,2015,13(5):361-367.
[27] 庞伦祥,何劲松,刘钧超.心房颤动离子通道重构的研究进展[J].医学综述,2007,13(2):94-96.
[28] 丽英,杨艳敏,浦介麟,等.盐酸关附甲素对豚鼠和大鼠心肌细胞钾通道的阻断作用[J].中国心脏起搏与心电生理杂志,2006,20(3):255-258.
[29] Gao X,Pu JL,Yang YM,et al.Effects of Guanfu base A hydrochloride on heart L-type calcium channel of rat ventricular myocytes[J].Chin J New Drug,2006,15(22):1926-1929.
[30] Fuster V, Ryden EL, Asinger RW,et al. ACC/AHA /ESC Guidelines for the Management of Patients With Atrial Fibrillation:Executive Summary.A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and Policy Conferences(Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation)Developed in Collaboration With the North American Society of Pacing and Electrophysiology[J].Circulation,2001,104:2118-2150.
[31] 朱俊,杨艳敏,李萍,等.盐酸关附甲素注射液血流动力学作用研究[J].中国临床药理学杂志,2000,16(6):412-414.
[32] 梁岩,朱俊,杨艳敏,等.关附甲素对急性心肌缺血五指山小型猪血流动力学的影响[J].中国新药与临床杂志,2007,26(3):190-195.
[33] Liang Y,Zhu J,Yang YM,et al.Electrophysiological effects of acehytisine hydrochloride in a porcine model of acute corohary occlusion[J].Acta Pharm Sin,2006,34(11):1035-1039.
[34] 梁岩,朱俊,杨艳敏,等.盐酸关附甲素在五指山小型猪心肌梗死后慢性心功能异常模型中的电生理学作用[J].中国心脏起搏与心电生理杂志, 2007, 2l(3): 251-255.
[35] 梁岩,朱俊,杨艳敏,等.盐酸关附甲素对小型猪慢性心功能异常模型的血流动力学影响[J].中国循环杂志,2007,8(22):302-306.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[7]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[8]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[9]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[10]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]